antiretrovirals

1.

Ambitious national targets for getting people on treatment often not reflected in grant performance frameworks, GAC says

13 Dec 2017
The reason? “Limitations of budgets in the 2017-2019 allocations period”
GAC calls for urgent inter-agency discussions, with donor governments included

In its report to the Board on the third batch of grants it recommended for approval, the Grant Approvals Committee (GAC) said that it was very concerned that national programs have ambitious goals to continue scaling up antiretroviral therapy (ART), with the aim of achieving the 90-90-90 targets or even treating all patients diagnosed with HIV – but that these goals are not necessarily reflected in performance frameworks because of “limitation

1.

Global Fund Board approves a second batch of grants for 2017-2019

28 Nov 2017
Twenty funding requests yielded 32 grants
10.

Audit of Global Fund grants to Mali reveals significant progress in financial management and quality of services

28 Nov 2017
However, there are problems with drug expiries, stock-outs and delays in the supply chain
1.

New government in Macedonia budgets for ARVs and prevention services to KAPs, as Global Fund support comes to an end

19 Sep 2017
Decision hailed as a “very important step in ensuring the sustainability of HIV services”
MOH will be required to establish a long-term mechanism for funding CSOs

On 5 September, the recently elected government of the Republic of Macedonia ordered the Ministry of Health to allocate 103 million Macedonian denars  (approximately € 1,674,000) within the National HIV Program for 2018 to (a) ensure continuous access to antiretroviral (ARV) treatment for HIV-positive people; and (b) support the implementation of HIV prevention programs among key affected populations (KAPs) such as men who have sex with men (M

3.

Global Fund pushes back on claims of overdependence on select suppliers of ARVs

17 Apr 2017
Buyers had been warned to diversify the manufacturing base or risk supply interruptions

The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.

2.

End-2015 results released

19 Jul 2016
Number of people on ARVs through programs supported by the Global Fund reaches 9.2 million

In the second half of 2015, through programs supported by The Global Fund, another 641,000 people were put on antiretroviral treatment (ART) for HIV, bringing the total to date to 9.2 million, a 7.5% increase over mid-2015 results and a 14.5% increase over the numbers a year ago.

7.

Results to mid-2015 released

6 Feb 2016
Number of people on ARVs reaches 8.6 million

In the first half of 2015, through programs supported by The Global Fund, another 500,000 people were put on antiretroviral treatment for HIV, bringing the total to date to 8.6 million, a 7% increase over end-2014 results.

10.

Major focus on sustainability in November funding approvals

7 Dec 2015
Even low-income countries are affected

Sustainability was a prominent theme in the November report of the Grant Approvals Committee to the Board. Ten of the 22 grants recommended for approval had already taken some steps towards sustainability or included measures in their proposed programs. Three of the 10 grants were from low income countries.

Subscribe to antiretrovirals